Alexion rises on Roche buyout rumor; no comment from companies
This article was originally published in Scrip
Alexion Pharmaceuticals could command a high price for its rare disease-focused portfolio, but the company and purported suitor Roche have not confirmed or denied that the Swiss pharma giant is interested in buying the US biotechnology company.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.